NANTES, France – (BUSINESS WIRE) – Regulatory news:
Pherecydes Pharma (FR0011651694 – ALPHE) (Paris: ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and / or complicated bacterial infections, today announced that its PhagoPROD project, which is partially funded by the European Commission , was presented in the magazine CORBIS. To read the article, please click on this link.
CORBIS is the European Commission’s magazine highlighting the most strategic research and development projects funded by the European Union (EU).
PhagoPROD is one of the elements in the development of Pherecydes Pharma, benefiting from Horizon 20/20 funding, which enables the company to implement all manufacturing processes required to manufacture phages in accordance with Good Manufacturing Practices (GMP). These high pharmaceutical quality phages are necessary to start clinical trials and make them available to healthcare professionals as part of the Early Access program. This project, funded by the European Union with 2.4 million euros, was initiated at the end of 2018 and revised in 2020.
Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, Conditions: “We are delighted to have been selected by the European Commission to appear in this edition of CORDIS. At a time when biological medicines have become a strategic priority, the EU supports us in implementing manufacturing processes for products that aim to mitigate the effects of the impending public health tsunami brought about by resistant and / or intricate bacterial Decreasing infections caused could be responsible for more than 10 million deaths each year by 20501. Thanks to this funding received in 2018 and the network of European partners we have built, we know how to produce batches of Good Manufacturing Practice (GMP) phages in Europe and henceforth paves the way for the large-scale development of phage therapy“.
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company developing treatments for resistant bacterial infections, which are responsible for many serious infections. The company has developed an innovative approach, precision phage therapy, which is based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria that are responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy was successfully applied in 22 patients as part of compassionate use under the supervision of the French National Agency for Drug Safety (ANSM). Pherecydes Pharma is headquartered in Nantes and has a team of around twenty experts from the pharmaceutical, biotechnology and academic research sectors.
For more informations, www.pherecydes-pharma.com
Disclaimer of Liability
This press release contains non-factual elements including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current visions and assumptions of the company management. They involve known and unknown risks and uncertainties that can lead to material differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, lawyers and employees have not verified the accuracy of any statistical or forecast information contained in this press release, whether originated or derived, and make no representations or warranties thereof from third party sources or industry publications; this statistical and forecast information is used in this press release for informational purposes only. Finally, this press release can be written in French and English. In the event of discrepancies between the two texts, the French version takes precedence.
1 Jim O’Neill Report, 2016